Emplicure has received a research grant from Vinnova

The project "Ceramic drug carrier for tamper resistant oral drug delivery" has a total budget of SEK 2.6 million, of which Vinnova contributes SEK 1.0 million. The project aims to develop a formulation and manufacturing method for mechanically hard drug-loaded ceramic carriers with intended use for opioid use disorder or moderate to severe pain.

Each prescription of opioids carries an inherent risk of addiction. The abuse and misuse of prescription opioids frequently serve as the starting point for a lifelong struggle with addiction, emphasizing the urgent need for multiple measures to prevent addiction and overdoses.

"We are very happy about this contribution for the further development of our bioceramic material and the collaboration within SweDeliver, which strengthens the knowledge exchange in the pharmaceutical delivery area in a very positive way," says Emplicure's CEO Håkan Engqvist.

The project  is a  collaboration with Uppsala University, the Department of Materials Science and the competence center SweDeliver. SweDeliver is a world-leading research and competence center in drug delivery that promotes interdisciplinary collaboration between academia and industry.

"This financial reinforcement to SweDeliver's consortium provides further opportunities to conduct innovative research, of great importance and benefit for patients who are currently without optimal treatment," says Christel Bergström, director of SweDeliver.

For additional information, please contact

Håkan Engqvist
CEO
Phone: +46 702 569 500
Email: [email protected]

Erik Magnusson
CFO
Phone: +46 708 565 245
Email: [email protected]

Certified Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

The following documents can be retrieved from beQuoted
PM-Emplicure Vinnova ENG -2023-09-15.pdf

Emplicure uses patented bioceramic technology to develop innovative and effective products to help consumers and patients live better lives. Our consumer division makes tiny, long-lasting and flavorful nicotine pouches that can be an alternative to smoking. Our pharmaceutical division develops safer and tamper-resistant treatments for pain. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com

If you want to open the text in your webbrowser click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected]

beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.

Vi hoppas att Du uppskattar denna service.